ArticleFrontiers in oncology2022

Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors.

Peng Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.